Turn Biotechnologies Licenses Revolutionary Technology to Unwind the Effects of Aging at a Cellular Level
Turn Biotechnologies, a Shanda VC portfolio company developing medicines for currently untreatable age-related conditions, announced that it has acquired the global rights for new technology that reprograms cells to undo many of the effects of aging.
You might also interested in
-
WhizAI Closes New Round with Investment from Shanda Group and AmerisourceBergen Bringing Total Capital Raised to $21 Million
SOMERSET, N.J.–(BUSINESS WIRE)–WhizAI, the first and only augmented analytics platform purpose built for the life sciences and healthcare industries, has […] -
Foundation Capital Invests in Vibe Capital, a New Venture Firm Built for Scrappy International Founders
Limited partners in Vibe Capital include Bessemer Venture Partners, Tribe Capital and Foundation Capital, as well as individuals including GSV […] -
Digital therapy maker Pear Therapeutics shakes the money tree, with plans to go public in $1.6B SPAC deal
One of Shanda’s portfolio companies, the digital treatment developer Pear Therapeutics, is taking the SPAC track, going public through a […]